IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
IN8bio, Inc. (NASDAQ: INAB) announces a publication in Frontiers in Immunology discussing their novel gamma-delta T cell therapy for glioblastoma. The therapy, DeltEx Drug Resistance Immunotherapy (DRI), aims to enhance the immune response against GBM while minimizing toxicity to healthy tissues. IN8bio's Phase 1 trial shows promising results with a possible improvement in progression-free survival.
The recent publication regarding IN8bio's novel gamma-delta T cell therapy, particularly for glioblastoma (GBM), is a significant development in the field of oncology and immunotherapy. The challenges in treating GBM, such as rapid tumor growth and antigen heterogeneity, have made it difficult for existing therapies to be effective. The unique approach of combining standard chemotherapy with genetically engineered gamma-delta T cells to resist lymphodepletion is noteworthy. This method, aiming to enhance immune response while reducing toxicity, could potentially extend progression-free survival (PFS) and overall survival (OS) for GBM patients beyond the current standards.
IN8bio's Phase 1 trial results indicating that all patients exceeded median PFS compared to standard-of-care therapy alone are promising. However, it is crucial to consider the small sample size and the early phase of the trial. The long-term efficacy and safety of the therapy, as well as its scalability and cost-effectiveness, will be essential factors in determining its impact on the market and patient care. The upcoming Phase 2 clinical trial will be a critical step in validating these preliminary findings and establishing the therapy as a viable treatment option.
The utilization of gamma-delta T cells in the context of adoptive cellular therapy represents a cutting-edge advancement in oncology. Gamma-delta T cells have the innate ability to recognize and kill cancer cells, making them an attractive option for immunotherapy. The DeltEx Drug Resistance Immunotherapy (DRI) specifically targets the NKG2D ligands, which are upregulated in GBM cells, thus providing a tailored approach to combat this aggressive cancer. The intracranial delivery of these modified cells, in conjunction with temozolomide, is an innovative strategy that could potentially lead to better management of GBM.
As an oncologist, the improvement in PFS observed in the Phase 1 trial is encouraging, as GBM is notorious for poor prognosis and limited treatment options. However, it is imperative to observe the outcomes of the larger and longer-term Phase 2 trial to truly understand the benefits and risks associated with this therapy. The potential to improve survival and quality of life for GBM patients is substantial, but the results must be reproducible and consistent in a diverse patient population to change the standard of care.
IN8bio's announcement of their novel gamma-delta T cell therapy's progress is likely to have a positive impact on the company's valuation and investor interest, especially considering the unmet medical need in GBM treatment. The biopharmaceutical sector places a high premium on innovative treatments that can demonstrate an ability to improve patient outcomes in conditions with limited therapeutic options. The data suggesting an improvement in PFS could be a strong catalyst for the company's stock, provided these results can be replicated in Phase 2 trials and beyond.
Furthermore, if IN8bio's therapy proves to be successful, it could capture a significant share of the GBM treatment market, which is projected to grow due to the increasing incidence of brain tumors. The potential market size and the therapy's impact on patient care could make IN8bio an attractive acquisition target for larger pharmaceutical companies looking to expand their oncology pipeline. However, investors should be aware of the risks associated with clinical trials and the regulatory hurdles that lie ahead before the therapy can be commercialized.
02/14/2024 - 08:00 AM
Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive cellular therapy
NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc Frontiers in Immunology
Cellular therapies, particularly chimeric antigen receptor T cell therapies (CAR-T), have shown promise in hematologic malignancies but have faced significant challenges when applied to solid tumors like GBM. These obstacles include rapid tumor growth, antigen heterogeneity, and limited response to current therapies.
The publication, titled: “Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions ,” explains the mechanism of action behind IN8bio’s novel therapeutic approach called DeltEx Drug Resistance Immunotherapy (DRI) and the current strategy and future directions for this treatment.
The INB-200 and INB-400 studies by IN8bio addresses the challenges towards targeting solid tumors by harnessing the innate immune functions of gamma-delta T cells. GBM cells constitutively express stress-associated NKG2D ligands (NKG2DL), which can be further upregulated through the DNA damage response (DDR) pathway triggered by alkylating agents like temozolomide (TMZ).
“We believe our results to date represent a significant advancement in the treatment of GBM. By combining standard chemotherapy with gamma-delta T cells genetically engineered to resist the lymphodepleting effects of chemotherapy, we are creating a synergistic effect that enhances the immune response against GBM while minimizing toxicity to healthy tissues,” said Lawrence Lamb, Ph.D., Chief Scientific Officer and Co-Founder of IN8bio. “This new treatment may improve the survival and quality of life of patients with GBM by preventing tumor recurrence and enhancing the immune response to eliminate residual cancer cells.”
The current standard of care for newly diagnosed GBM typically involves primary tumor resection followed by six weeks of chemoradiation therapy, succeeded by six cycles of monthly maintenance therapy with TMZ. This regimen typically yields a median progression-free survival (PFS) of 6 to 7 months and an overall survival (OS) ranging from 14 to 16 months. IN8bio‘s Phase 1 trial (INB-200) assessing the safety and efficacy of intracranial infusions of autologously derived DeltEx DRI gamma-delta T cells in addition to standard-of-care maintenance therapy suggests that the therapy is manageable with a possible improvement in PFS.
In the Phase 1 study, cells from the patient are isolated, expanded and modified prior to being delivered intracranially to the tumor cavity every month in combination with maintenance TMZ. The trial assesses three different dosing regimens from a single dose delivered on cycle 1, day 1 in Cohort 1, to three doses delivered on day 1 of cycles 1-3 in Cohort 2, to six doses delivered on day 1 of cycles 1-6 in Cohort 3. All patients receive 1x107 cells per dose. The trial aims to improve PFS by targeting residual cancer cells. Of the eight patients who have completed scheduled dosing, all have exceeded the median PFS expected with standard-of-care therapy alone.
IN8bio is also conducting a Phase 2 clinical trial of a genetically modified autologous gamma-delta T cell therapy (INB-400) targeting newly diagnosed GBM. The study will assess the safety, efficacy and tolerability of genetically modified DeltEx DRI cells at leading medical centers across the United States.
About INB-200
INB-200 is the first genetically engineered gamma-delta T cell therapy to be administered to patients with solid tumors and our initial indication is in GBM.
About INB-400
About IN8bio
IN8bio has initiated a Phase 2 trial of INB-400 in GBM at multiple centers across the United States and has two ongoing Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other hematological and solid tumor cancers. For more information about IN8bio and its programs, please visit www.IN8bio.com
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the ability of CAR-T cellular therapies to treat hematologic malignancies and GBM; the ability of the INB-200 study (i) to present a significant advancement in the treatment of GBM, (ii) create a synergistic effect that enhances the immune response against GBM while minimizing toxicity to healthy tissues and (iii) improve the survival and quality of life of patients with GBM by preventing tumor recurrence and enhancing the immune response to eliminate residual cancer cells; the ability of IN8bio’s Phase 1 trial in INB-200 to improve PFS by targeting residual cancer cells; and extending IN8bio’s cash runway into 2025; IN8bio’s ability to extend runway upon receipt of additional capital from the December 2023 private placement; IN8bio’s ability to raise additional capital from the December 2023 private placement; IN8bio’s ability to advance its work in other solid tumor indications; the potential for INB-400 to treat GBM; the timing of initiation, progress and scope of clinical trials for IN8bio’s product candidates, including INB-100, INB-200 , INB-300 and INB-400; and IN8bio’s ability to achieve anticipated milestones, including expected data readouts from its trials, enrollment of additional patients in its clinical trials and advancement of clinical development plans. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones, presented by public health crises as well as rising inflation and regulatory developments; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may not realize the intended benefits of its DeltEx platform; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; expectations for regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 9, 2023, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Company Contact info@IN8bio.com
Investors IN8bio@argotpartners.com
Media Contact kimberly.ha@kkhadvisors.com
What is the novel therapeutic approach developed by IN8bio for solid tumors like glioblastoma?
IN8bio has developed a novel therapeutic approach called DeltEx Drug Resistance Immunotherapy (DRI) using gamma-delta T cells to target solid tumors like glioblastoma.
What are the challenges faced in treating solid tumors like glioblastoma with cellular therapies?
Challenges in treating solid tumors like glioblastoma with cellular therapies include rapid tumor growth, antigen heterogeneity, and limited response to current therapies.
What is the current standard of care for newly diagnosed glioblastoma?
The current standard of care involves primary tumor resection followed by chemoradiation therapy and maintenance therapy with temozolomide.
What are the key findings from IN8bio's Phase 1 trial (INB-200) for glioblastoma treatment?
IN8bio's Phase 1 trial showed promising results with a possible improvement in progression-free survival by using intracranial infusions of autologously derived DeltEx DRI gamma-delta T cells in addition to standard-of-care maintenance therapy.
What is the Phase 2 clinical trial (INB-400) by IN8bio focusing on?
The Phase 2 clinical trial by IN8bio is focusing on assessing the safety, efficacy, and tolerability of genetically modified autologous gamma-delta T cell therapy targeting newly diagnosed glioblastoma.
